Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (RBR-7tmjyd9) titled 'How a Medication that increases Glucose Elimination through the Kidneys may affect inflammation and blood vessel health in people with Obesity' on July 21.
Study Type: Intervention
Study Design:
3, randomized-controlled, double-blind
Primary Sponsor: Universidade Federal de São Paulo - UNIFESP
Condition:
Obesity, Abdominal
Insulin Resistance
Obesity
E-66
Intervention:
This is a randomized, double-blind, placebo-controlled crossover clinical trial evaluating dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, compared with placebo in 50 adults with obesity and insulin resistance. Participants...